Thrivent Financial For Lutherans grew its position in Chemours Company (The) (NYSE:CC) by 8.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,190 shares of the specialty chemicals company’s stock after buying an additional 2,990 shares during the period. Thrivent Financial For Lutherans’ holdings in Chemours Company (The) were worth $1,411,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Financial Architects Inc increased its position in Chemours Company (The) by 1,230.3% in the 2nd quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after buying an additional 2,719 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Chemours Company (The) by 2,138.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after purchasing an additional 2,973 shares during the last quarter. Schroder Investment Management Group acquired a new stake in shares of Chemours Company (The) during the first quarter worth $156,000. Smithfield Trust Co. grew its position in shares of Chemours Company (The) by 521.4% in the second quarter. Smithfield Trust Co. now owns 4,791 shares of the specialty chemicals company’s stock valued at $182,000 after purchasing an additional 4,020 shares during the period. Finally, United Capital Financial Advisers LLC purchased a new stake in shares of Chemours Company (The) in the first quarter valued at $203,000. 72.90% of the stock is owned by institutional investors.

Several equities analysts recently weighed in on the company. UBS AG reissued a “sell” rating and set a $36.00 price objective (up previously from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. BidaskClub lowered shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research upgraded Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $61.00 price target on the stock in a research report on Tuesday. Argus reissued a “buy” rating and set a $55.00 price target (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. Finally, Jefferies Group LLC boosted their price target on Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Chemours Company (The) has a consensus rating of “Buy” and a consensus target price of $52.75.

In other Chemours Company (The) news, VP Amy Trojanowski sold 2,500 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider E Bryan Snell sold 10,000 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 38,837 shares of company stock valued at $1,865,603 in the last ninety days. 1.14% of the stock is currently owned by insiders.

Shares of Chemours Company (NYSE CC) opened at 53.44 on Wednesday. The company has a 50 day moving average of $51.00 and a 200 day moving average of $51.00. Chemours Company has a 1-year low of $14.41 and a 1-year high of $53.47. The company has a market cap of $9.88 billion, a PE ratio of 34.97 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the business posted $0.27 earnings per share. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities analysts expect that Chemours Company will post $3.51 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 17th were paid a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is presently 8.11%.

TRADEMARK VIOLATION WARNING: “Chemours Company (The) (CC) Stake Boosted by Thrivent Financial For Lutherans” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/chemours-company-the-cc-stake-boosted-by-thrivent-financial-for-lutherans/1607006.html.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.